CEL-SCI shares surge 11.32% premarket as renewed focus on Multikine's 14.1% Phase 3 survival benefit drives investor optimism.

CEL-SCI (CVM) surged 11.32% in premarket trading as renewed focus on Multikine’s 14.1% overall survival benefit in a 10-year Phase 3 trial for head and neck cancer drove optimism. The stock’s rally aligns with investor re-evaluation of long-term clinical data and corporate governance updates, including a revised Shareholder Rights Agreement approved by the board to strengthen strategic control ahead of 2026 regulatory milestones. The revised governance framework, coupled with a $10 million public offering, signaled financial and operational readiness, reinforcing confidence in Cel-Sci’s neoadjuvant immunotherapy platform. The premarket move reflects heightened anticipation for Multikine’s potential regulatory progress and the company’s alignment with emerging trends in early immune activation for oncology.